OTLK
What one share of Outlook Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a biopharmaceutical company that has developed ONS-5010/LYTENAVATM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD.
Outlook Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.75 |
|---|---|
| Cash and investments | $0.06 |
| Debt | $0.05 |
| Book value | −$0.06 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$586.90 | $10.21 | −$432.98 | — | −$36.30 |
| 2017 | — | −$288.00 | $1.94 | −$105.13 | — | −$215.94 |
| 2018 | — | −$194.72 | $11.28 | −$145.25 | — | −$56.59 |
| 2019 | — | −$39.62 | $0.48 | −$35.98 | — | −$11.28 |
| 2020 | — | −$13.47 | — | −$8.76 | — | $0.44 |
| 2021 | — | −$6.96 | — | −$7.11 | — | $0.52 |
| 2022 | — | −$6.23 | — | −$5.34 | — | $0.77 |
| 2023 | — | −$4.72 | — | −$3.44 | — | −$1.11 |
| 2024 | — | −$4.06 | — | −$3.71 | — | −$3.06 |
| 2025 | $0.04 | −$1.79 | — | −$1.49 | — | −$0.60 |